According to EY's latest white paper, the top 25 global biopharmaceutical companies are expected to face a potential business growth gap of 100 billion US dollars by 2028, and the gap will exceed 370 billion US dollars by 2032.

Zhitongcaijing · 3d ago
According to EY's latest white paper, the top 25 global biopharmaceutical companies are expected to face a potential business growth gap of 100 billion US dollars by 2028, and the gap will exceed 370 billion US dollars by 2032.